Submission and guidelines
Here you can find the form to send the abstract and the guidelines
Accepted Submission
Submission of any systematic investigation intended to produce new knowledge and/or approaches involving process or outcome variables. Submission of an abstract describing animal experimentation or involving the use of human subjects requires IRB approval number.
Required headings: Background, Objective, Methods, Results, and Conclusion.
Presentation of scientific documentation of a single clinical observation to improve knowledge of the clinical manifestations, diagnostic approaches, or therapeutic alternatives for a rare or unusual clinical condition or disease.
Required headings: Background, Case description, Discussion, Conclusion.
Submission of ongoing or completed projects, including educational programs, that demonstrate novel and innovative methods for examining and/or improving the effectiveness and efficiency of a program or policy.
Required headings: Background, Objective, Methods, Results, Conclusion.
Presentation of methods to evaluate and improve professional practice performance using quality improvement methodology.
Required headings: Purpose/Objectives, Design/Methods, Results, and Conclusion/Discussion.
Presentation
Panel Discussion on Pediatrics
Abstracts will be grouped in the format of Panel Discussions on Pediatrics or abstracts and can be accepted for an oral or a poster presentation.
These sessions provide an opportunity to group and discuss relevant material related to Pediatrics.
Sessions are led by an expert moderator and include 3-4 panelists in a 60-minute session.
Oral presentations are 15 minutes (10 minute/presentation; 5 minute/discussion)
Are two hours in length and include general viewing and author attendance period
Category
Abstract submissions are welcome on the following topics
• General Pediatrics and Primary Care Pediatrics
• Neonatology, Neonatal Pathology and Neonatal Intensive Care (NICU)
• Perinatology and Maternal – Fetal Medicine
• General Pediatric Gastroenterology and Primary Care
• Pediatric Disorders of Gut–Brain Interaction (DGBI: Colic, Functional Abdominal Pain)
• Pediatric Gastrointestinal and Bowel Dysmotility (Constipation, Functional Diarrhea)
• Pediatric Inflammatory Bowel Disease (IBD: Crohn’s Disease, Ulcerative Colitis)
• Pediatric Celiac Disease, Enteropathies and Food Intolerances
• Pediatric Epithelial Permeability and Gastrointestinal Barrier Dysfunction
• Pediatric Hepatology, Biliary Tract and Pancreatic Disorders
• Pediatric Gut Microbiome and Dysbiosis
• Diagnostic and Therapeutic Pediatric Gastrointestinal Endoscopy
• General and Outpatient Adult Gastroenterology
• Irritable Bowel Syndrome (IBS) and Visceral Hypersensitivity in Adults
• Functional Gastrointestinal Disorders and Adult Dysmotility (Dyspepsia, Reflux, Chronic Constipation)
• Adult Inflammatory Bowel Disease (IBD)
• Adult Celiac Disease, Non-Celiac Gluten Sensitivity and Enteropathies
• Enteric Manifestations and Gastrointestinal Prodromes of Neurodegenerative Diseases
• Adult Hepatology, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD/MASH) and the Gut–Liver Axis
• Digestive Physiology and Gastrointestinal Motility
• Advanced Adult Gastrointestinal Endoscopy and Functional Diagnostics
• Child and Adolescent Neuropsychiatry
• Developmental Pediatrics and Neurodevelopmental Disorders (ASD, ADHD)
• Pediatric Neurology
• Adult Neurology
• Clinical and Translational Neuroscience
• Clinical Neurophysiology and Functional Neuroimaging
• Neuroimmunology
• Neurodegenerative Diseases and Adult Dementias (Parkinson’s Disease, Cognitive Decline)
• Child, Adolescent and Transitional Psychiatry
• Adult Psychiatry and Mood Disorders
• Pediatric Allergy and Clinical Immunology
• Adult Allergy and Clinical Immunology
• Pediatric and Adult Immunorheumatology
• Pediatric and Neonatal Clinical Nutrition
• Adult Clinical and Preventive Nutrition and Dietetics
• Feeding and Eating Disorders (FED/Eating Disorders)
• Clinical and Functional Metabolomics
• Metabolomics of the First 1,000 Days and Neonatal Profiling
• Pediatric Metabolomics and Neurodevelopmental Disorders (ASD, ADHD)
• Gastrointestinal and Enteric Metabolomics
• Metabolomics of Neurodegenerative Diseases and Aging
• Nutritional Metabolomics and Dietary Selectivity
• Host–Microbiota Co-Metabolomics and Dysbiotic Metabolites
• Lipidomics and Lipid Mediators of Inflammation
• Mass Spectrometry and Nuclear Magnetic Resonance (NMR) in Clinical Research
• Metabolic Biomarkers of Biological Barriers (Gut and BBB)
• Pharmacometabolomics and Individual Therapeutic Response
• Clinical Microbiology, Virology and Parasitology
• Microbiome Sciences and Metagenomics
• Molecular, Cellular and Medical Genetics
• Clinical and Molecular Epigenetics
• Experimental Neurobiology and Preclinical Models
• Clinical Pharmacology, Toxicology and Experimental Therapies
• Medical and Pharmaceutical Biotechnology
• Microbiome Modulation Therapies (FMT, Strain-Specific Probiotics, Psychobiotics, Postbiotics)
• Immunonutrition and Intestinal Mucosal Pathophysiology
• Clinical Physiology, Neuromodulation (t-VNS) and Medical Bioengineering
• Internal Medicine
• Geriatrics and Gerontology
• Pediatric Endocrinology and Metabolic Disorders
• Adult Endocrinology, Diabetology and Metabolic Disorders
• Neuroendocrinology and the HPA Stress Axis
• Pediatric and Adult Sleep Medicine
• Clinical Epidemiology, Research Methodology and Public Health
• Pediatric Allergy and Clinical Immunology
• Adult Allergy and Clinical Immunology
• Pediatric and Adult Immunorheumatology
• Pediatric and Neonatal Clinical Nutrition
• Adult Clinical and Preventive Nutrition and Dietetics
• Feeding and Eating Disorders (FED/Eating Disorders)
• Clinical and Functional Metabolomics
• Metabolomics of the First 1,000 Days and Neonatal Profiling
• Pediatric Metabolomics and Neurodevelopmental Disorders (ASD, ADHD)
• Gastrointestinal and Enteric Metabolomics
• Metabolomics of Neurodegenerative Diseases and Aging
• Nutritional Metabolomics and Dietary Selectivity
• Host–Microbiota Co-Metabolomics and Dysbiotic Metabolites
• Lipidomics and Lipid Mediators of Inflammation
• Mass Spectrometry and Nuclear Magnetic Resonance (NMR) in Clinical Research
• Metabolic Biomarkers of Biological Barriers (Gut and BBB)
• Pharmacometabolomics and Individual Therapeutic Response
• Clinical Microbiology, Virology and Parasitology
• Microbiome Sciences and Metagenomics
• Molecular, Cellular and Medical Genetics
• Clinical and Molecular Epigenetics
• Experimental Neurobiology and Preclinical Models
• Clinical Pharmacology, Toxicology and Experimental Therapies
• Medical and Pharmaceutical Biotechnology
• Microbiome Modulation Therapies (FMT, Strain-Specific Probiotics, Psychobiotics, Postbiotics)
• Immunonutrition and Intestinal Mucosal Pathophysiology
• Clinical Physiology, Neuromodulation (t-VNS) and Medical Bioengineering
• Internal Medicine
• Geriatrics and Gerontology
• Pediatric Endocrinology and Metabolic Disorders
• Adult Endocrinology, Diabetology and Metabolic Disorders
• Neuroendocrinology and the HPA Stress Axis
• Pediatric and Adult Sleep Medicine
• Clinical Epidemiology, Research Methodology and Public Health
Rules for Abstract Submission
• The abstracts will be approved every month at the end of the month
• Authors are required to indicate their preference for either ORAL or POSTER presentation by checking the appropriate box on the submission web page. The UpMed Free Communications Committee will make the final decision on the format of presentation (i.e. poster or oral). Few selected posters will be scheduled for short oral presentation.
• Acceptance or rejection of abstracts will be based on rankings given by a peer review of experts in the associated topic/category. Results of the selection process will be sent via e-mail to the corresponding author.
The Committee decision is final and cannot be appealed.
• Abstracts cannot be identical to any abstract that has previously been presented at a major international meeting prior. An update to prior work is acceptable.
• Instructions on the preparation of posters and information regarding projection facilities will be included with the notification of acceptance.
• Submission of an abstract indicates that:
- the author(s) agree to comply with the abstract submission and presentation rules
- the presentation is based on scientific and/or clinical methods that are ethical and valid
- all authors have contributed to and approve the abstract and its entire contents.
• All accepted abstracts will be published electronically on digital media (e.g. CD-ROM) as well as on the UpMed 2026 website, and distributed to all delegates.
• Accepted abstracts are official communications of the Congress. The presenting author agrees to register, attends the Congress, and presents the abstract as scheduled by the UpMed Congress.
The presenting author MUST REGISTER FOR THE UPMED BY February 2027 before the abstract can officially be accepted for inclusion in the final scientific program and official Program Book.
• The evaluation and scoring of the abstract (acceptance as poster or as oral communication, or rejection) will be made according to a number of criteria, including:
- Scholarly and/or research validity
- Educational value
- Clarity of presentation
- Potential impact on global pediatrician
INSTRUCTIONS FOR ABSTRACT PREPARATION (Refer to the Abstract sample for specific guidance on formatting)
• Abstracts must be written and presented in English. Abstracts that are not written in understandable English will be rejected and/or returned to the author(s) for revision.
• Title: Use a concise descriptive title that indicates the content of the abstract. The complete title should be CAPITALIZED and in bold. Please minimize the use of abbreviations in the title. Commercial trade names for drugs, devices, products, and services may NOT be used in the title.
• Authors: Names and surnames for each author must be provided. Do not include degrees or titles. Presenting authors’ names should be underlined.
• Affiliations: Each author should be listed by department, institution, city, and country.
• Keyword(s): A minimum of one (1), and a maximum of three (3) keywords reflecting the contents of the abstract should be provided.
• Abstracts should not exceed 400 WORDS (2600 characters excluding spaces). The submission program will automatically calculate the size of your abstract and will not allow submissions that do not fit in the size requirements. Symbols including superscripts and subscripts can be entered in the online system.
The body of the abstract text must be formatted with the following sub-headings as appropriate. Each sub-heading should be formatted in bold text, begin on a new line, and followed by a colon and space. The text for each sub-section should begin immediately after the colon and space (see sample abstract below). For clinical or investigative studies:
- Introduction
- Objective
- Materials and Methods
- Results
- Conclusions
For case reports or case series:
- Background
- Observation
- Key message
It is NOT satisfactory to simply state that “The results will be discussed.” Only common and standard abbreviations may be used without definition.
NO REFERENCES, TABLES, CHARTS OR IMAGES ARE ALLOWED.
Check spelling and grammar carefully. Direct reproduction from your electronically submitted abstract text means that any errors in spelling, grammar or scientific data will be reproduced as submitted. Drugs, devices, products, and services should be identified by generic name only within the abstract.
The use of commercial drug names, brands and registered trademarks are strictly prohibited. No mention of pharmaceutical company names should be included in the abstract. Data must be given in units (International metric system is preferred) that are generally accepted in scientific publications.
RESIDENTS AND FELLOWS FORUM
The UpMed Congress will schedule a special Forum during the Congress to feature extended oral presentations by pediatrician residents and fellows on basic or clinical research. Individuals will be chosen for this Forum based on the scientific quality and impact of their work as judged by the UpMed Free Communications Committee.
When submitting your abstract online, select the applicable box if you are a Resident or Fellow and you wish to be considered for this Forum. You may also wish to consider applying for a UpMed 2027 Scholarship if you are submitting your abstract for this session.
IMPORTANT DEADLINES AND MANDATORY DECLARATIONS
• Online Submission will be available on the Congress website.
Please follow the instructions detailed on the website. Your abstract submission will be acknowledged automatically by email, but this confirmation does not constitute official acceptance for presentation.
FAX SUBMISSIONS WILL NOT BE ACCEPTED.
- Statement of Responsibility
- All co-authors must agree with the submitted results and conclusions, and consent to being listed as authors.
- The abstract must not have been submitted in identical format to any other international meeting.
- Work involving humans or animals, or material derived from them must have been approved by an institutional ethics committee.
- All authors must complete a Disclosure of Conflicting Relationships declaration form.
- Modifications to the abstract may be made before the online abstract submission system is closed after 15 February 2027 the abstract has already been accepted by the UpMed Free Communications Committee.
Authors who wish to withdraw their abstract must send a written request to: info@upmedcongress.com.
UPMED 2027 SCHOLARSHIPS AND ABSTRACT AWARDS
Scholarships will be provided by the UpMed 2027 to assist participants from around the world to present their work at the UpMed. Scholarships will be awarded on the basis of merit and relative financial need as judged by the UpMed 2027 Scholarship and Awards Committee.
Please refer to the Scholarship and Awards section of the website for the adjudication criteria. Awards will also be provided to outstanding oral and poster presentations.
For more information please contact:
UpMed Congress 2027 Secretariat: Leukasia Eventi
mail: eventi@leukasia.it